




## Rapid, Targeted Cancer Screening — From Sample to Results in Under 15 Minutes.



**Nu.Q® on Element i+ is the industry's only in-house canine cancer screening blood test, exclusively offered by Antech**

Nu.Q® utilizes breakthrough technology to help assess the current likelihood of certain cancers, including lymphoma and hemangiosarcoma.

### **Reliable and convenient in-house cancer screening test**

Only requires 50µL of EDTA plasma from a patient. High (>70%) detection rates for lymphoma.



### **Innovative cancer assessment**

Measures canine plasma nucleosome concentration to help determine likelihood of certain cancers, oftentimes sooner than traditional wellness screening.

### **Affordable testing and immediate results**

Refine your differential list in minutes, helping you inform pet owners of risk level for common cancer types — all at an affordable cost for pet owners.

### **Seamless integration into routine wellness**

Efficient workflow makes it easy to add Nu.Q® to routine wellness diagnostics for high-risk patients.

Nu.Q® is a registered trademark of VolitionRx Limited and is supplied under license by Volition RX Limited and its subsidiaries 43868-001

# Nu.Q® on Element i+ Offers Early Detection for Best Prognosis.

One in four dogs develop cancer,  
and often diagnosed far too late.<sup>1</sup>

Nu.Q® is an Accessible, Affordable,  
and Quantitative Blood Test For  
Plasma Nucleosomes in Dogs.

## Indications:

- Older dogs ( $\geq$  7 years of age)
- Younger dogs ( $\geq$  4 years of age) for breeds known to be at a higher risk of developing cancer
  - Labrador Retriever
  - French Bulldog
  - Golden Retriever
  - German Shepherd
  - Beagle
  - Rottweiler
  - Boxer
  - Pembroke Welsh Corgi
  - Great Dane
  - Miniature schnauzer
  - Siberian Husky
  - Bernese Mountain Dog
  - Mastiff
  - Irish Wolfhound
  - Flat-coated Retriever
  - Scottish Wolfhound

Nucleosomes can become elevated before traditional wellness screening parameters alerting disease may be present sooner. Nu.Q® on the Element i+ also allows clinicians to interpret results and develop a plan of action before your patient goes home.

Determine the current likelihood of certain cancers like lymphoma and hemangiosarcoma with Nu.Q® instantly, with technology at your fingertips

## Element i+™

### Immunodiagnostic Analyzer

Supports diagnostic needs with total T4, cortisol, progesterone, cTSH, and the Nu.Q® cancer test.



## In-clinic Nu.Q®

Discover the speed, accuracy, and flexibility of Element i+ combined with affordable, immediate in-house cancer risk evaluation using the Nu.Q® test

### PEER-REVIEWED STUDIES

Lymphoma paper: [pubmed.ncbi.nlm.nih.gov/34399763/](https://pubmed.ncbi.nlm.nih.gov/34399763/)

Hemangiosarcoma paper: [pubmed.ncbi.nlm.nih.gov/34187493/](https://pubmed.ncbi.nlm.nih.gov/34187493/)

2020 cancer vs healthy dogs: [pubmed.ncbi.nlm.nih.gov/32866177/](https://pubmed.ncbi.nlm.nih.gov/32866177/)

\*Nu.Q® is not a confirmatory test for cancer. Nu.Q® results should act as an impetus to perform additional diagnostics to discern a diagnosis. Elevated plasma nucleosome concentration does not indicate which cancer is present, and further diagnostics will be needed. Certain inflammatory conditions may increase plasma nucleosome concentration and in these instances Nu.Q® cannot differentiate between cancer and an inflammatory response.

### REFERENCES:

1. Cancer in Pets. American Veterinary Medical Association. (2022). Retrieved 9 July 2022, from [avma.org/resources/pet-owners/petcare/cancer-pets](https://avma.org/resources/pet-owners/petcare/cancer-pets)
2. National Cancer Institute: [ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-ono#:~:text=It%20has%20been%20estimated%20that,in%20cats%20made%20each%20year](https://ccr.cancer.gov/Comparative-Oncology-Program/pet-owners/what-is-comp-ono#:~:text=It%20has%20been%20estimated%20that,in%20cats%20made%20each%20year)